Trimetaphan camsilate 250mg/5ml solution for injection ampoules
A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Trimetaphan
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
3 branded products available
MHRA licensed products
View all licensed products for Trimetaphan on the MHRA register
Trimetaphan camsilate 250mg/5ml solution for injection ampoules
Trimetaphan camsilate 250mg/5ml solution for injection ampoules
Trimetaphan camsilate 250mg/5ml solution for injection ampoules
Alliance Healthcare (Distribution) Ltd
WHO defined daily dose (DDD)
250 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
1957–2003
Showing the 50 most relevant studies, sorted by most relevant.
J. Turner, D. Powell, R. Gibson, et al.
British journal of anaesthesia, 1977
- Hypotension, Controlled
- Ferricyanides
- Nitroprusside
Boorman JP, Beato M, Groot-Kormelink PJ, et al.
2003
- Oocytes
- Neurons
- Xenopus laevis
We compared the main properties of human recombinant alpha3beta4beta3 neuronal nicotinic receptors with those of alpha3beta4 receptors, expressed in Xenopus oocytes. beta3 incorporation decreased the channel mean open time (from 5.61 to 1.14 ms, after approximate correction for missed gaps) and burst length. There was also an increase in single channel slope conductance from 28.8 picosiemens (alpha3beta4) to 46.7 picosiemens (alpha3beta4beta3; in low divalent external solution). On the other hand, the calcium permeability (determined by a reversal potential method in chloride-depleted oocytes) and the pharmacological properties of beta3-containing receptors differed little from those of alpha3beta4. The main pharmacological difference in alpha3beta4beta3 "triplet" receptors was a 3-fold decrease in the potency of lobeline relative to acetylcholine. Nevertheless, there was no change in the rank order of potency for agonists (epibatidine >> lobeline > cytisine, 1,1-dimethyl-4-phenylpiperazinium iodide, nicotine > acetylcholine > carbachol for both receptors; measured at low agonist concentrations). Sensitivity to the competitive antagonists trimetaphan (0.2-1 microM) and dihydro-beta-erythroidine (30 microM) was similar for the two combinations, with a Schild KB for trimetaphan of 76 and 66 nM on alpha3beta4 and alpha3beta4beta3, respectively. The change in single channel conductance confirms that beta3 replaces a beta4 subunit in the pentamer. The absence of pronounced differences in the pharmacological profile of the triplet receptor argues against a role for the beta3 subunit in the formation of agonist binding sites, whereas the changes in channel kinetics suggest an important effect on receptor gating. The shortening of the burst length of beta3-containing receptors implies that any synaptic currents mediated by such channels would have faster decay kinetics.
Abstract licence: CC BY
T. Ishikawa, D. Mcdowall
British journal of anaesthesia, 1981
- Ferricyanides
- Nitroprusside
- Trimethaphan
D. Scott, G. Stephen, R. Marshall, et al.
British journal of anaesthesia, 1972
W. MacRAE, J. Wildsmith, B. Dale
Anaesthesia, 1981
- Ferricyanides
- Nitroprusside
- Trimethaphan
J. Wildsmith, C. J. Sinclair, J. Thorn, et al.
British journal of anaesthesia, 1983
- Hypotension, Controlled
- Otorhinolaryngologic Diseases
- Ferricyanides
Tetsuya Tono, Y. Ueki, N. Nagata, et al.
Acta oto-laryngologica. Supplementum, 1998
- Cochlea
- Hypotension
- Trimethaphan
W. Thomas, P. Cole, N. Etherington, et al.
British journal of anaesthesia, 1985
- Ferricyanides
- Nitroprusside
- Trimethaphan
N. Saitoh, K. Mikawa, S. Kitamura, et al.
British journal of anaesthesia, 1991
- Intubation, Intratracheal
- Trimethaphan
- Laryngoscopy
R. A. Theye, G. Tuohy, D. Little
British journal of anaesthesia, 1965
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
8 found
Half-life
Not available
Mechanism
Trimethaphan is a ganglionic blocking agent prevents stimulation of postsynaptic…
Food interactions
None known
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1059 interactions
Proteins and enzymes this drug interacts with in the body
Expressed in the inner ear, in sympathetic neurons and in other non-neuronal cells, such as skin keratinocytes and lymphocytes .
PMID:11752216 PMID:15531379
nAChR formed by CHRNA9:CHRNA10 is involved in modulation of auditory stimuli. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane. In the ear, mediates synaptic transmission between efferent olivocochlear fibers and hair cells of the cochlea, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing .
PMID:11752216
This may protect against acoustic trauma.
May also regulate keratinocyte adhesion (By similarity)
PMID:22361591 PMID:27698419 PMID:29720657 PMID:38454578
CHRNA4 forms heteropentameric neuronal acetylcholine receptors with CHRNB2 and CHRNB4, as well as CHRNA5 and CHRNB3 as accesory subunits. Is the most abundant nAChR subtype expressed in the central nervous system .
PMID:16835356 PMID:22361591 PMID:27698419 PMID:29720657 PMID:38454578
Found in two major stoichiometric forms,(CHRNA4)3:(CHRNB2)2 and (CHRNA4)2:(CHRNB2)3, the two stoichiometric forms differ in their unitary conductance, calcium permeability, ACh sensitivity and potentiation by divalent cation .
PMID:27698419 PMID:29720657 PMID:38454578
Involved in the modulation of calcium-dependent signaling pathways, influences the release of neurotransmitters, including dopamine, glutamate and GABA (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC C02BA01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Trimethaphan
Matched from: Trimetaphan
Additional database identifiers
ChemSpider
22044
BindingDB
82545
HUGO Gene Nomenclature Committee (HGNC)
HGNC:13800
GenAtlas
CHRNA10
GeneCards
CHRNA10
GenBank Gene Database
AJ278118
GenBank Protein Database
12053839
Guide to Pharmacology
470
UniProt Accession
ACH10_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:1958
GenAtlas
CHRNA4
GeneCards
CHRNA4
GenBank Gene Database
L35901
GenBank Protein Database
755648
Guide to Pharmacology
465
UniProt Accession
ACHA4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:983
GenAtlas
BCHE
GeneCards
BCHE
GenBank Gene Database
M32391
GenBank Protein Database
1311630
Guide to Pharmacology
2471
UniProt Accession
CHLE_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72